INmune Bio Inc
NASDAQ:INMB

Watchlist Manager
INmune Bio Inc Logo
INmune Bio Inc
NASDAQ:INMB
Watchlist
Price: 1.7 USD -1.73% Market Closed
Market Cap: 45.2m USD

Operating Margin

-102 752%
Current
Declining
by 36 433.7%
vs 3-y average of -66 318.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-102 752%
=
Operating Income
$-51.4m
/
Revenue
$50k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-102 752%
=
Operating Income
$-51.4m
/
Revenue
$50k

Peer Comparison

Country Company Market Cap Operating
Margin
US
INmune Bio Inc
NASDAQ:INMB
46m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 14 112 companies
1st percentile
-102 752%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

INmune Bio Inc
Glance View

Market Cap
45.2m USD
Industry
Biotechnology

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2019-02-04. The firm is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). The company has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer's and treatment-resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.

INMB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-102 752%
=
Operating Income
$-51.4m
/
Revenue
$50k
What is INmune Bio Inc's current Operating Margin?

The current Operating Margin for INmune Bio Inc is -102 752%, which is below its 3-year median of -66 318.3%.

How has Operating Margin changed over time?

Over the last 3 years, INmune Bio Inc’s Operating Margin has decreased from -6 668.2% to -102 752%. During this period, it reached a low of -304 535.7% on Dec 31, 2024 and a high of -6 668.2% on Aug 30, 2022.

Back to Top